Gene · 5921
NIH grants2,330
NIH grants whose papers are about the gene, through NIH's grant-paper links.
581 to 600 of 2,330
Download this page as JSON| Grant | Title | RASA1 papers | Newest fiscal year |
|---|---|---|---|
| U01HG007709 | BCM Clinical Site for an Undiagnosed Disease Network (UDN) Phase II (U01) | 1 | 2022 |
| U19AI171292 | RAPIDLY EMERGING ANTIVIRAL DRUG DEVELOPMENT INITIATIVE- AViDD CENTER (READDI-AC) | 1 | 2022 |
| U54CA233223 | THE RNA HELICASE EIF4A IS A THERAPEUTIC VULNERABILITY IN TRIPLE-NEGATIVE BREAST CANCER | 1 | 2022 |
| UL1TR002649 | Center for Clinical and Translational Research | 1 | 2022 |
| ZIABC004504 | Interacting Signaling Pathways that Initiate Squamous Cell Carcinogenesis | 1 | 2022 |
| ZIABC005445 | Pathways that Suppress or Accelerate Premalignant Progression of Squamous Cancer | 1 | 2022 |
| ZIABC010833 | Colorectal Cancer Transcriptome: Effects of Genomic Instability and Aneuploidy | 1 | 2022 |
| ZIABC010837 | Disease prognostication and treatment response in rectal cancer patients | 1 | 2022 |
| ZIABC012061 | Prediction of Therapy Response in Colorectal Cancer | 1 | 2022 |
| ZIADC000016 | NF-kappaB in pathogenesis and therapy of head and neck cancer | 1 | 2022 |
| ZIAHG200330 | Comparative Genomics Analysis Unit Research | 1 | 2022 |
| P01CA087497 | Roles and Regulation of wild-type and mutant forms of p53 | 3 | 2021 |
| R01CA207288 | Development of SHP2 inhibitors for targeted anti-cancer therapy | 3 | 2021 |
| T32GM007753 | Medical Scientist Training Program | 3 | 2021 |
| R01CA065823 | Characterizing the landscape of resistance and persistence mechanisms in CML | 2 | 2021 |
| R01CA205158 | p190 RhoGAP signaling in epithelial oncogenesis | 2 | 2021 |
| R01CA213278 | Reprogramming Tumor Microenvironment by Nanoparticle | 2 | 2021 |
| R01GM124233 | Decoding the structures and lipid binding specificity of small GTPase membrane anchors | 2 | 2021 |
| R01MH112151 | Characterization of SynGAP Mutations in Human Cognitive Disorders | 2 | 2021 |
| R25GM059994 | The Meharry RISE initiative | 2 | 2021 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5921/grants?page=30